Responsiveness to anti-tumour necrosis factor α therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients

Annals of the Rheumatic Diseases

Volumn 67, Issue 4, 2008, Pages 563-566

  Van Der Pouw Kraan, T C M ^a   Wijbrandts, C A ^b   Van Baarsen, L G ^a   Rustenburg, F ^a   Baggen, J M ^a   Verweij, C L ^a   Tak, P P ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INFLIXIMAB; METHOTREXATE; NEUTRALIZING ANTIBODY; PREDNISONE; TRANSCRIPTION FACTOR; TRANSCRIPTOME; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INFLAMMATION; JOINT BIOPSY; MALE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BINDING SITES; BIOPSY; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SYNOVIAL MEMBRANE; SYNOVITIS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 41849115276     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.081950     Document Type: Article

References (15)

1. Tak PP, Smeets TJ, Daha MR, Kluin PM, Meijers KA, Brand R, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997;40:217-25.
2. van der Pouw Kraan TC, Van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC, et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 2003;48:2132-45.
3. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
4. Smeets TJ, Kraan MC, van Loon ME and Tak PP. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003;48:2155-62.
5. Wittkowski H, Foell D, Af Klint E, De Rycke L, De Keyser F, Frosch M, et al. Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis. Ann Rheum Dis 2007;66:1020-5
6. van Roon JA, Hartgring SA, Wenting-van Wijk M, Jacobs KM, Tak PP, Bijlsma JW, et al. Persistence of IL-7 activity and IL-7 levels upon TNFα blockade in patients with rheumatoid arthritis. Ann Rheum Dis 2006;66:664-9.
7. van Gestel AM, Haagsma CJ and van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
8. Demeter J, Beauheim C, Gollub J, Hernandez-Boussard T, Jin H, Maier D, et al. The Stanford Microarray Database: implementation of new analysis tools and open source release of software. Nucleic Acids Res 2007;35:D766-D70.
9. Nielsen TO, West RB, Linn SC, Alter O, Knowling MA, O'Connell JX, et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 2002;359:1301-7.
10. Thomas PD, Kejariwal A, Guo N, Mi H, Campbell MJ, Muruganujan A, et al. Applications for protein seguence-function evolution data: mRNA/protein expression analysis and coding SNP scoring tools. Nucleic Acids Res 2006;34:W645-W50.
11. Loots GG, Ovcharenko I, Pachter L, Dubchak I and Rubin EM. rVista for comparative sequence-based discovery of functional transcription factor binding sites. Genome Res 2002;12:832-9.
12. Lindberg J, Af Klint E., Catrina AI, Nilsson P, Klareskog L, Ulfgren AK, et al. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. Arthritis Res Ther 2006;8:R179.
13. Aletaha D, Funovits J, Keystone EC and Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis Rheum 2007;56:3226-35.
14. Wei G, Guo J, Doseff AI, Kusewitt DF, Man AK, Oshima RG, et al. Activated Ets2 is required for persistent inflammatory responses in the motheaten viable model. J Immunol 2004;173:1374-9.
15. Fedele M, Benvenuto G, Pero R, Majello B, Battista S, Lembo F, et al. A novel member of the BTB/POZ family, PATZ, associates with the RNF4 RING finger protein and acts as a transcriptional repressor. J Biol Chem 2000;275:7894-901.